Abstract: A method of measuring retinal or visual pathway function comprises stimulating optokinetic nystagmus by presenting a visual stimulus to a patient; modifying a first parameter of the visual stimulus; modifying a second parameter of the visual stimulus; and using the modified visual stimulus to determine a threshold stimulus for optokinetic nystagmus; wherein the first and second parameters are selected from a group of parameters comprising a pattern for the visual stimulus, a width of the visual stimulus, a distance between the visual stimulus and the patient, a spatial frequency of the visual stimulus, a rate of change or temporal frequency of the test face of the visual stimulus, and a contrast between elements of the visual stimulus.

Abstract: Use of L-carnitine and/or one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of a dietary supplement or medicament for the treatment of corneal diseases is disclosed.

Abstract: Various embodiments of the present invention are directed toward a method for preparing probiotic nanoparticles from natural sources, comprising performing a biological preparation phase such as isolating any cells derived from either prokaryote or eukaryote cells, performing a chemical preparation phase such as performing an enzymatic procedure (or heating, or chemicals) for killing or obtaining cell derived ingredients, performing a physical preparation phase such as performing ultrasonication, and performing a formulation preparation phase such as powderized drying.

Abstract: A method of measuring retinal or visual pathway function comprises stimulating optokinetic nystagmus by presenting a visual stimulus to a patient; modifying a first parameter of the visual stimulus; modifying a second parameter of the visual stimulus; and using the modified visual stimulus to determine a threshold stimulus for optokinetic nystagmus; wherein the first and second parameters are selected from a group of parameters comprising a pattern for the visual stimulus, a width of the visual stimulus, a distance between the visual stimulus and the patient, a spatial frequency of the visual stimulus, a rate of change or temporal frequency of the test face of the visual stimulus, and a contrast between elements of the visual stimulus.

Abstract: A method of measuring retinal or visual pathway function comprises stimulating optokinetic nystagmus by presenting a visual stimulus to a patient; modifying a first parameter of the visual stimulus; modifying a second parameter of the visual stimulus; and using the modified visual stimulus to determine a threshold stimulus for optokinetic nystagmus; wherein the first and second parameters are selected from a group of parameters comprising a pattern for the visual stimulus, a width of the visual stimulus, a distance between the visual stimulus and the patient, a spatial frequency of the visual stimulus, a rate of change or temporal frequency of the test face of the visual stimulus, and a contrast between elements of the visual stimulus.

Abstract: Composition and method for preventing, treating or attenuating inflammatory diseases by way of inhibiting lipid peroxidation and subsequent elementary inflammation through ensuring the presence of the following biologically active ingredients in the PMRS of cells involved in inflammation: i) at least one killed probiotic and ii) at least one omega 3 FA and iii) vitamin E and iv) ubiquinone by introducing a composition comprising any of the missing ingredients.

Abstract: Use of L-carnitine and/or one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of a dietary supplement or medicament for the treatment of corneal diseases is disclosed.

Abstract: The visual function is determined with the help of test images, comprising inducing photostress induced by illuminating the eye with an intense light, then measuring the time needed for the recovery of the visual function before the illumination. The test images are periodically moving test images, and the visual function is determined on the basis of detecting the phenomenon of optokinetic nystagmus. According to another process the visual function is determined by measuring critical fusion frequency (CFF) before and after the photostress.

Abstract: The visual function is determined with the help of test images, comprising inducing photostress induced by illuminating the eye with an intense light, then measuring the time needed for the recovery of the visual function before the illumination. The test images are periodically moving test images, and the visual function is determined on the basis of detecting the phenomenon of optokinetic nystagmus. According to another process the visual function is determined by measuring critical fusion frequency (CFF) before and after the photostress.

Abstract: The invention is related to the preparation of a pharmaceutical composition containing a bile acid component and a bioflavonoid component. The pharmaceutical composition according to the invention may be used for the treatment of digestive disoreders, systemic diseases associated with digestive disorders and diseases, furthermore for improving the digestion and absorption of the fat-soluble vitamins of foods, essential fatty acid and food components as well as food additives.

Abstract: Compositions containing as active ingredients a lipid-soluble benzoquinone, e.g. Coenzyme Q10 and at least one omega-3 polyunsaturated fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linolenic acid (LNA), for the prevention and/or treatment of mitochondriopathies.

Abstract: A three-dimensional logical toy having regular, irregular or amorphous composite members of various shapes as symbol-bearing components and forming a unit, whereby the shaped members making up the composite body may be allocated to three main groups within which the configurations are identical, and whereby the shaped bodies may be rearranged by rotation along the axis traversing the geometrical central point of the composite body. The composite enclosing body (1) is made up of 18 shaped members (2, 3, 4) falling into three different groups and arranged in three mutually parallel layers, which are delimited by two surfaces, viz. one having the configuration of a regular hexagram and one parallel thereto having the configuration of a regular hexagonal. The body is shaped as a composite, form-locked enclosing body along the surface of hexagram configuration.

Abstract: The present invention relates to synergistic pharmaceutical compositions for the treatment of liver disorders comprising 5-aminoimidazole-4-carboxamide orthophosphate (AICA-phosphate) as active ingredient in association with vitamins, preferably with vitamin B and/or E and optionally with other pharmaceutical excipients.